Leucine-Rich, Glioma-Inactivated Protein 1 Antibody, IgG CBA-IFA with Reflex to Titer, Serum
Aid in diagnosis of leucine-rich glioma inactivated 1 protein (LGI1) antibody disorders associated with limbic encephalitis, hyponatremia, and myoclonic movements. Disorders are rarely associated with tumors. Use to manage antibody-positive (LGI1) individual following immunotherapy and/or plasmapheresis.
Semi-Quantitative Cell-Based Indirect Fluorescent Antibody
New York DOH Approval Status
Serum separator tube.
Separate serum from cells within 2 hours of collection. Transfer 1 mL serum to an ARUP standard transport tube. (Min: 0.2 mL)
CSF or plasma. Contaminated, hemolyzed, or severely lipemic specimens.
After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year (avoid repeated freeze/thaw cycles)
Less than 1:10
Leucine-rich, glioma-inactivated 1 protein (LGI1) IgG antibody may occur as part of the voltage-gated potassium channel (VGKC) complex antibodies.
The presence of LGI1 IgG antibody is mainly associated with limbic encephalitis, hyponatremia, and myoclonic movements. LGI1 IgG antibody is rarely associated with tumors but may occur infrequently in Morvan syndrome, neuromyotonia, and idiopathic epilepsy. The full spectrum of clinical disorders associated with the LGI1 IgG antibody continues to be defined. Results should be interpreted in correlation with the patient's clinical history and other laboratory findings.
This indirect fluorescent antibody assay utilizes LGI1 transfected cell lines for the detection and semiquantification of the LGI1 IgG antibody.
Laboratory Developed Test (LDT)
If LGI1 antibody IgG is positive, then LGI1 antibody IgG titer will be added. Additional charges apply.
86255; if reflexed, add 86256
|Component Test Code*||Component Chart Name||LOINC|
|2009457||LGI1 Ab IgG CBA-IFA Screen, Serum||82978-8|